1-(3-chlorophenyl)piperazine has been researched along with Obsessive-Compulsive Disorder in 41 studies
1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure
1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.
Obsessive-Compulsive Disorder: An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effect of fluoxetine on serotonergic sensitivity in obsessive-compulsive disorder (OCD), the partial serotonin agonist metachlorophenylpiperazine (mCPP) was compared to placebo under double-blind conditions in six patients with OCD before and during treatment with fluoxetine." | 9.07 | Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder. ( DeCaria, C; Gorman, JM; Gully, R; Hollander, E; Klein, DF; Liebowitz, MR; Nitescu, A; Suckow, RF, 1991) |
| "Clomipramine is a potent serotonin reuptake blocker that decreases the symptoms of obsessive-compulsive disorder (OCD)." | 9.06 | Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. ( Hill, JL; Insel, TR; Murphy, DL; Zohar, J; Zohar-Kadouch, RC, 1988) |
| "To evaluate the role of serotonin (5-HT) function in obsessive-compulsive disorder (OCD), behavioral and biochemical responses to the 5-HT receptor agonist m-chlorophenylpiperazine (MCPP) and the 5-HT precursor tryptophan were examined in healthy subjects and patients with OCD." | 7.67 | Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. ( Charney, DS; Goodman, WK; Heninger, GR; Price, LH; Rasmussen, SA; Woods, SW, 1988) |
| "Pretreatment with ondansetron did not affect any of the self-rated behavioral symptoms." | 6.69 | Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results. ( Broocks, A; Canter, S; Grady, TA; Hill, JL; L'Heureux, F; Murphy, DL; Pigott, TA, 1998) |
| " The doses of modulators were selected on the basis of dose-response studies." | 5.39 | Effects of agomelatine in a murine model of obsessive-compulsive disorder: interaction with meta-chlorophenylpiperazine, bicuculline, and diazepam. ( Bhutada, P; Deshmukh, P; Dixit, P; Kaulaskar, S; Thakur, K, 2013) |
| "To investigate the effect of fluoxetine on serotonergic sensitivity in obsessive-compulsive disorder (OCD), the partial serotonin agonist metachlorophenylpiperazine (mCPP) was compared to placebo under double-blind conditions in six patients with OCD before and during treatment with fluoxetine." | 5.07 | Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder. ( DeCaria, C; Gorman, JM; Gully, R; Hollander, E; Klein, DF; Liebowitz, MR; Nitescu, A; Suckow, RF, 1991) |
| "Clomipramine is a potent serotonin reuptake blocker that decreases the symptoms of obsessive-compulsive disorder (OCD)." | 5.06 | Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. ( Hill, JL; Insel, TR; Murphy, DL; Zohar, J; Zohar-Kadouch, RC, 1988) |
| "We have proposed rewarded T-maze alternation as a model of obsessive-compulsive disorder (OCD): the serotonin agonist m-chlorophenylpiperazine (mCPP) increments persistence therein, while chronic pretreatment with selective serotonin reuptake inhibitor (SSRI fluoxetine) but not benzodiazepine or desipramine abolishes mCPP effects." | 3.74 | Dopaminergic and serotonergic modulation of persistent behaviour in the reinforced spatial alternation model of obsessive-compulsive disorder. ( Boulougouris, V; Kalogerakou, S; Kontis, D; Papadimitriou, GN; Papadopoulos, S; Papakosta, VM; Poulopoulou, C; Tsaltas, E, 2008) |
| "To evaluate the role of serotonin (5-HT) function in obsessive-compulsive disorder (OCD), behavioral and biochemical responses to the 5-HT receptor agonist m-chlorophenylpiperazine (MCPP) and the 5-HT precursor tryptophan were examined in healthy subjects and patients with OCD." | 3.67 | Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. ( Charney, DS; Goodman, WK; Heninger, GR; Price, LH; Rasmussen, SA; Woods, SW, 1988) |
| " Each subject was tested two times, receiving both times the same dosage of mCPP or placebo with ritanserin or placebo pre-treatment." | 2.73 | Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo. ( de Leeuw, AS; Westenberg, HG, 2008) |
| "Pretreatment with ondansetron did not affect any of the self-rated behavioral symptoms." | 2.69 | Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results. ( Broocks, A; Canter, S; Grady, TA; Hill, JL; L'Heureux, F; Murphy, DL; Pigott, TA, 1998) |
| " The doses of modulators were selected on the basis of dose-response studies." | 1.39 | Effects of agomelatine in a murine model of obsessive-compulsive disorder: interaction with meta-chlorophenylpiperazine, bicuculline, and diazepam. ( Bhutada, P; Deshmukh, P; Dixit, P; Kaulaskar, S; Thakur, K, 2013) |
| "desipramine) treatment (both 10 mg/kg; 20 mg/kg x 21 days)." | 1.35 | Stereotypic behaviour in the deer mouse: pharmacological validation and relevance for obsessive compulsive disorder. ( Harvey, BH; Korff, S; Stein, DJ, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (14.63) | 18.7374 |
| 1990's | 20 (48.78) | 18.2507 |
| 2000's | 8 (19.51) | 29.6817 |
| 2010's | 6 (14.63) | 24.3611 |
| 2020's | 1 (2.44) | 2.80 |
| Authors | Studies |
|---|---|
| da Silva, JF | 1 |
| Taguchi, LM | 1 |
| Leite, EDS | 1 |
| de Oliveira, AR | 2 |
| Reimer, AE | 1 |
| Diniz, JB | 1 |
| Hoexter, MQ | 1 |
| Miguel, EC | 1 |
| Milad, MR | 1 |
| Brandão, ML | 1 |
| Bhutada, P | 1 |
| Dixit, P | 1 |
| Thakur, K | 1 |
| Deshmukh, P | 1 |
| Kaulaskar, S | 1 |
| Tucci, MC | 3 |
| Dvorkin-Gheva, A | 3 |
| Sharma, R | 1 |
| Taji, L | 2 |
| Cheon, P | 2 |
| Peel, J | 2 |
| Kirk, A | 2 |
| Szechtman, H | 3 |
| Johnson, E | 1 |
| Wong, M | 1 |
| de Leeuw, AS | 1 |
| Westenberg, HG | 2 |
| Kontis, D | 2 |
| Boulougouris, V | 1 |
| Papakosta, VM | 1 |
| Kalogerakou, S | 1 |
| Papadopoulos, S | 1 |
| Poulopoulou, C | 1 |
| Papadimitriou, GN | 1 |
| Tsaltas, E | 2 |
| Kreiss, DS | 1 |
| Coffman, CF | 1 |
| Fiacco, NR | 1 |
| Granger, JC | 1 |
| Helton, BM | 1 |
| Jackson, JC | 1 |
| Kim, LV | 1 |
| Mistry, RS | 1 |
| Mizer, TM | 1 |
| Palmer, LV | 1 |
| Vacca, JA | 1 |
| Winkler, SS | 1 |
| Zimmer, BA | 1 |
| Graham, D | 1 |
| Amodeo, S | 1 |
| Gross-Isseroff, R | 1 |
| Cohen, R | 1 |
| Sasson, Y | 1 |
| Voet, H | 1 |
| Zohar, J | 5 |
| Chrysikakou, S | 1 |
| Giannou, H | 1 |
| Biba, A | 1 |
| Pallidi, S | 1 |
| Christodoulou, A | 1 |
| Maillis, A | 1 |
| Rabavilas, A | 1 |
| Gráf, M | 1 |
| Korff, S | 1 |
| Stein, DJ | 6 |
| Harvey, BH | 1 |
| Goodman, WK | 4 |
| McDougle, CJ | 2 |
| Price, LH | 4 |
| Barr, LC | 3 |
| Hills, OF | 1 |
| Caplik, JF | 1 |
| Charney, DS | 3 |
| Heninger, GR | 2 |
| Hadigan, CM | 1 |
| Walsh, BT | 1 |
| Buttinger, C | 1 |
| Hollander, E | 12 |
| Cohen, LJ | 2 |
| DeCaria, C | 6 |
| Saoud, JB | 3 |
| Cooper, TB | 2 |
| Islam, NN | 1 |
| Liebowitz, MR | 6 |
| Klein, DF | 4 |
| DeCaria, CM | 2 |
| Prohovnik, I | 1 |
| Simeon, D | 2 |
| Islam, N | 1 |
| Hwang, M | 1 |
| Wong, CM | 1 |
| Grossman, R | 1 |
| Cohen, L | 2 |
| Rosen, J | 1 |
| Broocks, A | 1 |
| Pigott, TA | 3 |
| Hill, JL | 5 |
| Canter, S | 1 |
| Grady, TA | 1 |
| L'Heureux, F | 2 |
| Murphy, DL | 6 |
| Kwon, J | 1 |
| Weiller, F | 1 |
| Liebowitz, M | 1 |
| Ho Pian, KL | 1 |
| den Boer, JA | 1 |
| de Bruin, WI | 1 |
| van Rijk, PP | 1 |
| Baumgarten, HG | 1 |
| Grozdanovic, Z | 1 |
| Khanna, S | 1 |
| John, JP | 1 |
| Reddy, LP | 1 |
| Erzegovesi, S | 1 |
| Martucci, L | 1 |
| Henin, M | 1 |
| Bellodi, L | 1 |
| Rubenstein, CS | 1 |
| Bernstein, SE | 2 |
| Nitescu, A | 2 |
| Gully, R | 2 |
| Suckow, RF | 2 |
| Gorman, JM | 3 |
| Grover, GN | 1 |
| Zohar-Kadouch, RC | 3 |
| Bihari, K | 1 |
| Pato, MT | 1 |
| Winslow, JT | 1 |
| Insel, TR | 4 |
| Fay, M | 1 |
| Cohen, B | 1 |
| Campeas, R | 2 |
| Papp, L | 1 |
| Woods, SW | 1 |
| Rasmussen, SA | 1 |
| Mueller, EA | 1 |
4 reviews available for 1-(3-chlorophenyl)piperazine and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Meta-Chlorophenylpiperazine-Induced Behavioral Changes in Obsessive-Compulsive Disorder Research: A Systematic Review of Rodent Studies.
Topics: Animals; Male; Obsessive-Compulsive Disorder; Rats; Rats, Sprague-Dawley; Rats, Wistar; Rodentia; Se | 2022 |
Role of serotonin in obsessive-compulsive disorder.
Topics: Biogenic Monoamines; Fenfluramine; Humans; Neuropeptides; Obsessive-Compulsive Disorder; Piperazines | 1998 |
The serotonin hypothesis of obsessive compulsive disorder: implications of pharmacologic challenge studies.
Topics: Biomarkers; Clomipramine; Humans; Neurotransmitter Uptake Inhibitors; Obsessive-Compulsive Disorder; | 1992 |
Neurobiology of obsessive compulsive disorder: a possible role for serotonin.
Topics: Humans; Obsessive-Compulsive Disorder; Piperazines; Receptors, Serotonin; Serotonin | 1990 |
22 trials available for 1-(3-chlorophenyl)piperazine and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Hydrocortisone; Male; Middle Aged; Obsessiv | 2008 |
Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan.
Topics: Adult; Female; Humans; Hydrocortisone; Male; Middle Aged; Obsessive-Compulsive Disorder; Piperazines | 2004 |
m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation.
Topics: Administration, Oral; Adolescent; Adult; Affect; Anxiety; Arousal; Double-Blind Method; Female; Huma | 1995 |
Behavioral and neuroendocrine responses to metaCPP in anorexia nervosa.
Topics: Adult; Affect; Anorexia Nervosa; Arousal; Body Mass Index; Body Weight; Double-Blind Method; Female; | 1995 |
A pilot study of biological predictors of treatment outcome in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Ambulatory Care; Clomipramine; Dose-Response Relationship, Drug; Double-Blind Met | 1993 |
Induction of depersonalization by the serotonin agonist meta-chlorophenylpiperazine.
Topics: Adult; Animals; Arousal; Borderline Personality Disorder; Brain; Depersonalization; Double-Blind Met | 1995 |
Headache response to m-chlorophenylpiperazine in obsessive-compulsive disorder and normal controls.
Topics: Adolescent; Adult; Female; Headache; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Piper | 1996 |
Seasonal effects in prolactin response to m-chlorophenylpiperazine challenge in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Photoperi | 1996 |
Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results.
Topics: Adult; Analysis of Variance; Behavioral Symptoms; Double-Blind Method; Drug Interactions; Female; Hu | 1998 |
Serotonergic function in social phobia: comparison to normal control and obsessive-compulsive disorder subjects.
Topics: Adult; Analysis of Variance; Anxiety; Case-Control Studies; Female; Humans; Hydrocortisone; Male; Ne | 1998 |
Effects of meta-chlorophenylpiperazine on cerebral blood flow in obsessive-compulsive disorder and controls.
Topics: Adult; Cerebrovascular Circulation; Double-Blind Method; Female; Humans; Male; Obsessive-Compulsive | 1998 |
Neuroendocrine and behavioral responses to mCPP in Obsessive-Compulsive Disorder.
Topics: Administration, Oral; Adult; Arousal; Double-Blind Method; Female; Humans; Hydrocortisone; Hypothala | 2001 |
Low versus standard dose mCPP challenge in obsessive-compulsive patients.
Topics: Adult; Affect; Anxiety; Behavior; Cross-Over Studies; Disease Progression; Dose-Response Relationshi | 2001 |
A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder.
Topics: Adolescent; Adult; Blood Platelets; Double-Blind Method; Female; Humans; Male; Middle Aged; Obsessiv | 1992 |
Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Double-Blind Method; Down-Regulation; Female; Fenfluramine; | 1992 |
Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder.
Topics: Adult; Arousal; Brain; Female; Fluoxetine; Humans; Hydrocortisone; Male; Obsessive-Compulsive Disord | 1991 |
Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder.
Topics: Administration, Oral; Adult; Double-Blind Method; Drug Interactions; Female; Humans; Hydrocortisone; | 1991 |
Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings.
Topics: Adult; Clonidine; Fenfluramine; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Piperazine | 1988 |
Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology.
Topics: Adult; Brain; Clomipramine; Depressive Disorder; Desipramine; Diagnosis, Differential; Female; Human | 1987 |
More on self mutilation and obsessive compulsive disorder.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Fluoxetine; Humans; Male; Obsessive-Compulsive | 1988 |
Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment.
Topics: Adult; Aged; Brain Chemistry; Clinical Trials as Topic; Clomipramine; Double-Blind Method; Female; H | 1988 |
Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls.
Topics: Adult; Affect; Aged; Behavior; Body Temperature; Female; Humans; Male; Metergoline; Middle Aged; Obs | 1987 |
15 other studies available for 1-(3-chlorophenyl)piperazine and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Fear extinction in an obsessive-compulsive disorder animal model: Influence of sex and estrous cycle.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Estrous Cycle; Extinction, Psycho | 2018 |
Effects of agomelatine in a murine model of obsessive-compulsive disorder: interaction with meta-chlorophenylpiperazine, bicuculline, and diazepam.
Topics: Acetamides; Animals; Antidepressive Agents; Behavior, Animal; Bicuculline; Diazepam; Disease Models, | 2013 |
Separate mechanisms for development and performance of compulsive checking in the quinpirole sensitization rat model of obsessive-compulsive disorder (OCD).
Topics: Animals; Compulsive Behavior; Disease Models, Animal; Male; Obsessive-Compulsive Disorder; Piperazin | 2014 |
5-HT2A/C receptors do not mediate the attenuation of compulsive checking by mCPP in the quinpirole sensitization rat model of obsessive-compulsive disorder (OCD).
Topics: Animals; Compulsive Behavior; Disease Models, Animal; Male; Obsessive-Compulsive Disorder; Piperazin | 2015 |
Dopaminergic and serotonergic modulation of persistent behaviour in the reinforced spatial alternation model of obsessive-compulsive disorder.
Topics: Animals; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Fluoxetine; Ma | 2008 |
Ritualistic chewing behavior induced by mCPP in the rat is an animal model of obsessive compulsive disorder.
Topics: Animals; Behavior, Animal; Clomipramine; Diazepam; Disease Models, Animal; Dopamine Antagonists; Flu | 2013 |
Effects of the serotonergic agonist mCPP on male rats in the quinpirole sensitization model of obsessive-compulsive disorder (OCD).
Topics: Animals; Behavior, Animal; Compulsive Behavior; Disease Models, Animal; Dose-Response Relationship, | 2013 |
Reinforced spatial alternation as an animal model of obsessive-compulsive disorder (OCD): investigation of 5-HT2C and 5-HT1D receptor involvement in OCD pathophysiology.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Desipramine; Diazepam; Disease Model | 2005 |
5-HT2c receptor activation induces grooming behaviour in rats: possible correlations with obsessive-compulsive disorder.
Topics: Aminopyridines; Animals; Grooming; Indoles; Male; Obsessive-Compulsive Disorder; Piperazines; Quinol | 2006 |
Stereotypic behaviour in the deer mouse: pharmacological validation and relevance for obsessive compulsive disorder.
Topics: Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Desipramine; Disease Models, Animal; Do | 2008 |
The serotonin hypothesis of obsessive compulsive disorder.
Topics: Animals; Arousal; Brain; Humans; Hydrocortisone; Obsessive-Compulsive Disorder; Piperazines; Prolact | 1993 |
Timing of neuroendocrine responses and effect of m-CPP and fenfluramine plasma levels in OCD.
Topics: Adult; Female; Fenfluramine; Humans; Hydrocortisone; Male; Obsessive-Compulsive Disorder; Piperazine | 1993 |
Increased cerebral blood flow during m-CPP exacerbation of obsessive-compulsive disorder.
Topics: Administration, Oral; Adult; Aged; Cerebral Cortex; Female; Humans; Image Processing, Computer-Assis | 1995 |
Neurologic soft signs in obsessive-compulsive disorder.
Topics: Adult; Anxiety Disorders; Central Nervous System Diseases; Clomipramine; Clonidine; Depressive Disor | 1991 |
Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects.
Topics: Adult; Female; Growth Hormone; Humans; Hydrocortisone; Male; Obsessive-Compulsive Disorder; Personal | 1988 |